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Abstract: Maternal uterine artery blood flow is critical to maintaining the intrauterine environment,
permitting normal placental function, and supporting fetal growth. It has long been believed that
inadequate transformation of the maternal uterine vasculature is a consequence of primary defective
trophoblast invasion and leads to the development of preeclampsia. That early pregnancy maternal
uterine artery perfusion is strongly associated with placental cellular function and behaviour has
always been interpreted in this context. Consistently observed changes in pre-conceptual maternal
and uterine artery blood flow, abdominal pregnancy implantation, and late pregnancy have been
challenging this concept, and suggest that abnormal placental perfusion may result in trophoblast
impairment, rather than the other way round. This review focuses on evidence that maternal
cardiovascular function plays a significant role in the pathophysiology of preeclampsia.
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1. Introduction
Maternal uterine artery blood flow is one of the critical factors that contribute to the preservation
of the intrauterine environment, which permits normal placental function to support fetal growth and
development. This is so, not only because maternal blood carries nutrition and removes waste, but
also because oxygen delivered to the developing fetoplacental unit is directly limited by uterine blood
flow. Spiral arterioles that perfuse the intervillous space undergo significant morphologic changes
during this process, with uterine vascular adaptations resulting in five to 10-fold dilatation to meet the
requirements of the fetoplacental unit [1]. It has long been believed that inadequate development of
the uterine vasculature may be a consequence of primary defective placentation, which may lead to
the development of both preeclampsia and fetal growth restriction. Understanding the relationship
between uterine artery blood flow and placental development is fundamental to understanding normal
placentation and its disruption in both preeclampsia and fetal growth restriction. This review focuses
on the relationship between uterine artery blood flow and the trophoblast function, and discusses the
insights provided into the pathophysiology of preeclampsia.
2. Uterine Artery Blood Flow Assessment
Maternal uterine arteries can be readily and reliably identified via ultrasound by the use of
a color Doppler and the pulsatility index (resistance to blood flow), assessed concurrently with a
pulsed wave Doppler. Resistance to blood flow in the uterine arteries falls with advancing gestation,
a finding attributed to progressive trophoblastic invasion and transformation of the uterine spiral
Int. J. Mol. Sci. 2019, 20, 3263; doi:10.3390/ijms20133263 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 3263 2 of 14
arteries into large vessels of low resistance [2]. Failure to transform has been described in preeclampsia
and fetal growth restriction, resulting in the use of a uterine artery blood flow Doppler assessment
to screen for these pregnancy problems [3]. A recent review of reviews for preeclampsia screening
methods demonstrated that uterine artery Doppler assessment as a stand-alone test had the best
predictive value for the prediction of early-onset preeclampsia when compared to other tests with a
moderate predictive value, such as increased body mass index (BMI), placental growth factor (PLGF),
and placental protein 13 (PP13). The analysis also showed that no single biomarker met the standards
required for a clinical screening test, but that models, that combined markers, were more promising for
the prediction of preeclampsia [4]. In a recent randomized controlled trial, the use of such multimodal
screening to determine the risk of preterm preeclampsia, followed by the prescription of low-dose
Aspirin prophylaxis before 16 weeks’ gestation to the high-risk group, has been shown to halve the
risk of preterm preeclampsia [5,6].
3. Uterine Artery Doppler Indices and Trophoblast Biology
The process of implantation, trophoblast development, and spiral artery transformation must
involve many cellular and tissue processes to their effect. In view of the strong association between
high uterine artery Doppler indices and the subsequent development of preeclampsia and fetal
growth restriction, numerous authors have investigated trophoblast biology in samples obtained from
pregnancies demonstrating high or low uterine artery Doppler resistance. Persistence of high resistance
in the uterine artery Doppler indices in early pregnancy suggests that impaired trophoblast invasion
and inadequate spiral artery remodeling has occurred [7].
3.1. Cell Injury and Apoptosis
Several studies have shown that placental tissues obtained from women with high-resistance
uterine artery Doppler indices were more sensitive to apoptotic stimuli than placental tissue from
women with normal indices [8–10]. Charolidi et al. examined the effect of tumor necrosis factor alpha
(TNFα) on placental endothelial cell (PEC) apoptosis in the context of high vs. normal uterine artery
Dopplers (Figure 1). They demonstrated that placental endothelial cells (PECs) from the high resistance
index (RI) group exposed to TNFα had a 40% reduction in half-life compared to those from the normal
RI group which were exposed to TNFα [10].
Figure 1. Apoptosis of first-trimester placental endothelial cells (PEC) from normal (normal RI)
and high-resistance (high-RI) pregnancies in response to stimulation with TNFα and actinomycin D.
First-trimester PEC were cultured with 30 ng/mL TNFα and 800 ng/mL actinomycin D. Images were
taken every 15 min over 15 h. (a) The kinetics of the induction of apoptosis for PEC, high RI (n = 8 mean
± SEM, black symbols) and normal RI (n = 8 mean ± SEM, grey symbols). (b) In a separate cohort,
normal-RI PEC were incubated with TNFα and actinomycin D alone (n = 4), as well as in the presence
of the broad-spectrum caspase inhibitor, zVAD-fmk (n = 4). The results are expressed as mean ± SEM
and * p < 0.05. Adapted with permission from Charolidi et al. [9].
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3.2. Cell Motility and Penetration
During early placentation, trophoblast cells invade the endometrium and differentiate to form
the villous structure of the placenta. Extravillous trophoblast (EVT) migrates from said villi to attach
the placenta to the decidual stroma cells (DSC) of the uterus. Interstitial EVT invades through the
decidua into the myometrium, while endovascular EVT migrates into the lumen of the spiral arteries,
replacing vascular smooth muscle cells, leading to spiral artery transformation [11]. James-Allan et al.,
assessed DSC function in pregnancies with high or normal uterine artery Doppler resistance indices in
the first trimester. Their results showed that the chemoattraction of trophoblast cells by the DSC was
dysfunctional when the DSC was gathered from a pregnancy with high uterine artery resistance, thus
suggesting that there may be an interplay between the DSC and EVT in early pregnancy which might
play a role in impaired trophoblast invasion related to high-resistance uterine artery blood flow [12].
3.3. Cell-Cell Interaction
Decidual natural killer (dNK) cells make up about 70% of the leukocytes found in the decidua in
the first trimester [12]. dNK cells secrete a number of factors that disrupt vascular cell interactions
and allow for vascular smooth muscle cells to migrate out of the spiral arteries [13–15]. dNK cells
have also been shown to increase EVT motility by hepatocyte growth-factor secretion, leading to
chemoattraction of the EVT to the sites of remodeling [16]. Wallace et al. demonstrated that dNK cells
isolated during the first trimester from pregnancies with high uterine artery Dopplers have decreased
ability to chemoattract trophoblast cells and induce the outgrowth of the EVT from the villi when
compared to those from pregnancies with normal uterine artery resistance [17].
3.4. Oxidative Stress and Hypoxia
During the first trimester of pregnancy, the placenta develops in an environment with a relatively
low oxygen supply of only 20mmHg at 8 weeks, rising to >50 mmHg at 12 weeks, as the maternal
uterine artery blood flow increases [18]. Hypoxia-inducible nuclear factors HIF1α and HIF2α are
master regulators of the hypoxia response in tissues, and are also expressed in the early-pregnancy
placenta [19,20]. Levels of HIF1α are significantly lower in placentas gathered from pregnancies
with high uterine artery resistance despite the expectation that placental hypoxia or oxidative stress
would be associated with higher levels of HIF1α [8]. The latter tissues expressed an altered balance of
antioxidant enzyme activity (lower glutathione peroxidase and higher superoxide dismutase activity)
when compared with normal placental tissue. These findings all suggest that hypoxia and oxidative
stress appear to be a physiological state in early pregnancy.
3.5. Altered Gene Expression
Two studies of first-trimester placental samples at the time of chorionic villous sampling
demonstrated differences in gene expression when the woman subsequently developed preeclampsia
or fetal growth restriction compared to those who had a normal pregnancy outcome [21,22]. One study
which examined gene expression by microarray in first-trimester placentas demonstrated 26 genes
were variably expressed in women with high-resistance uterine artery indices. The genes that were
significantly differentially expressed included those mainly responsible for cell death/apoptosis, stress
response, inflammatory/immune response, and the metabolic and cyclooxygenase pathways [8].
These findings all suggest a close and likely causative association between early-pregnancy
uterine artery Doppler indices, trophoblast invasion, and the subsequent development of preeclampsia
(Figure 2). High uterine artery resistance indices are predictive of the development of preeclampsia,
and also influence trophoblast cell migration, apoptosis, motility, invasion, cell–cell interaction,
response to oxidative stress, and gene expression.
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Figure 2. Relationship between uterine artery perfusion and cellular function. There are strong
associations between maternal uterine artery perfusion and placental cellular function and behaviour.
High-resistance Doppler indices (poor placental perfusion) is related to abnormalities of cell motility,
penetration, and cell–cell interaction, as well as increased rates of oxidative stress, inflammation, cellular
injury, and apoptosis. Adapted with permission from Cartwright et al. [23].
4. Uterine Artery Blood Flow and Trophoblast Development—A Causality Paradox
The relationships demonstrated in the previous section between uterine artery blood flow and
trophoblast cell function/behavior have been conventionally interpreted as reflecting the process of
trophoblast invasion, causing decreased resistance to flow in the uterine artery. This hypothesis is
propagated by the long-held belief that impaired trophoblast development results in poor spiral artery
transformation and creates a predisposition to the development of preeclampsia. However, a number
of recent findings have led to the re-evaluation of the cause–effect inference between trophoblast
development and spiral artery transformation.
4.1. Abdominal Pregnancy
A recent case report described an advanced abdominal pregnancy where the placenta was
implanted outside the uterus in the right-lateral pelvic side wall [24]. The authors took the initiative to
describe the uterine artery Doppler findings, which demonstrated a low-resistance waveform consistent
with a normal pregnancy placentation. The question this observation raises is how complete spiral
artery transformation occurred in order to create the observed low-resistance uterine artery waveform
consistent with a normal pregnancy when the placenta was implanted in an extra-uterine site. Case
reports are often disregarded by scientists and clinical academics; however, in certain unique situations,
the exception observed in a single clinical case may prove (or disprove) the rule. However, the latter
finding has previously been consistently reported in extra-uterine pregnancy [25], and suggests that
changes observed universally in the maternal uterine and spiral arteries that are reflected by uterine
Doppler indices do not occur as a direct consequence of trophoblast invasion.
4.2. Late Pregnancy Uterine Artery Resistance Changes
Binder et al. studied 5887 pregnancies with longitudinal uterine Doppler assessment into the third
trimester. They found that one-third of patients demonstrated a de-novo increase in uterine artery
resistance in the late third trimester, having previously exhibited normal indices—and that this group
had a 30% higher prevalence of preeclampsia [26]. If the conventional paradigm that normal trophoblast
invasion causes spiral artery transformation and a decrease in uterine artery resistance is true, then the
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demonstration of an increase in third-trimester uterine artery resistance would require hypothetical
“de-transformation” of the spiral arteries—an implausible biological phenomenon. An alternative
explanation for the uterine artery Doppler findings in abdominal or late pregnancy is that observed
variations are not caused by localized trophoblast invasion, but may, in fact, reflect maternal systemic
vascular resistance changes [27,28].
4.3. Ophthalmic and Radial Artery Doppler Assessment
If, indeed, uterine artery waveform changes reflect maternal systemic hemodynamic perturbations
rather than trophoblast invasion, then the Doppler assessment of non-uterine arterial vessels should
mirror the findings in the uterine artery. Recent systematic reviews of Doppler assessment of the
radial and ophthalmic arteries in pregnancy have demonstrated that these vessels also reduce their
resistance with advancing gestation and demonstrate persistent high resistance in the first trimester in
pregnancies at increased risk of preeclampsia [29,30]. These vessels seem to have the same ability to
predict preeclampsia as the use of the uterine artery Doppler in isolation.
4.4. Pre-Pregnancy Maternal Systemic Vascular Resistance
Above all, the findings suggest that maternal systemic and uterine vascular resistance in pregnancy
changes independently of the direct physical consequences of placental invasion and trophoblast cell
behavior. If this were the case, it would imply that the biological associations described previously are
inversely causal—that is to say, that increased uterine resistance and poor placental perfusion may result
in impaired trophoblast invasion and function, rather than the other way around. The hypothesis that
maternal systemic and uterine vascular impairment predates placental maldevelopment is supported
by a recent prospective study assessing pre-pregnancy cardiovascular function in 530 women [31].
Women who subsequently developed preeclampsia had lower cardiac output and higher systemic
vascular resistance in the pre-pregnancy state prior to the development of the trophoblast. The authors
concluded that an altered pre-pregnancy hemodynamic phenotype was associated with the subsequent
development of preeclampsia and/or fetal growth restriction.
5. Reviewing Evidence Supporting Placental Origins of Preeclampsia
Etiology and pathophysiology are two specific terms referring to distinct processes. The former
refers to the origin of the disease, whilst pathophysiology refers to the biological mechanism by
which the disease manifests clinical signs and symptoms. Whilst the role of the placenta in the
pathophysiology of preeclampsia is indisputable, the observations supporting the hypothesis that
abnormal placentation is the etiology of preeclampsia are restricted to spiral artery transformation
(discussed above), abnormal placental histology, and fetal size.
5.1. Placental Histology in Preeclampsia
Preeclampsia has been attributed to maternal vascular malperfusion of the placental bed,
characterized by myometrial/decidual vascular lesions (incomplete or absent remodeling of maternal
spiral arteries) and, more commonly, placental villous lesions, such as accelerated villous maturation,
distal villous hypoplasia, increased syncytial knots, and villous infarction [32,33]. Notably, these
vascular and villous lesions are not specific to preeclampsia, and are also found in many other
pregnancy disorders, such as fetal growth restriction, spontaneous preterm labor, placental abruption,
and stillbirth [34,35]. A recent systematic review assessed the prevalence of vascular and villous
lesions in preeclamptic and normal pregnancies [36]. The authors demonstrated that placental villous
and vascular lesions were not seen in the majority of preeclamptic pregnancies (pooled prevalence
of 45.2% and 38.2% in all studies, respectively) and were also seen in 10–20% of normal pregnancies.
Interestingly, the authors also reported a three-fold overreporting of placental lesions in preeclampsia
when the pathologist was unblinded to the pregnancy diagnosis, compared to blind reporting [37].
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These findings show that the placental histological vascular and villous lesions previously presumed
to be characteristic of preeclampsia are neither specific nor sensitive markers of the disorder.
5.2. Fetal Size in Preeclampsia
Fetal growth restriction is considered a typical feature of preeclampsia resulting from the
primary placental dysfunction that causes the disorder. It is fetal growth restriction and associated
hypoxemia that predispose to increased risk of fetal, neonatal, and long-term adverse outcomes [38–40].
Epidemiological studies demonstrate that the majority of preterm preeclampsia cases result in
fetal growth restriction. However, over 80% of preeclampsia occurs at a term where the rate of
large-for-gestational-age births are as common as small-for-gestational-age births (both 15%), and most
neonates are of normal size, even after the exclusion of diabetic pregnancies [41,42]. The finding
of normal or excessive fetal growth in the majority of term preeclampsia cases is not consistent
with impaired trophoblast invasion with placental dysfunction being the primary etiological process
in preeclampsia.
6. Evidence for Cardiovascular Origins of Preeclampsia
Earlier, we outlined the strong associations between uterine artery blood flow and trophoblast
cell biology. The data also suggested that trophoblast invasion was not directly responsible for early
pregnancy changes in uterine, ophthalmic, and radial artery hemodynamics, leaving us to entertain
the alternative possibility that maternal cardiovascular function might be involved. If maternal
cardiovascular function plays such an etiological role, this should also be evident from the epidemiology
of preeclampsia.
6.1. Predisposing Factors for Preeclampsia
It is not entirely apparent how maternal clinical risk factors for preeclampsia, such as advanced
maternal age, ethnicity, obesity, diabetes, hyperlipidemia, renal dysfunction, and chronic hypertension
influence trophoblast invasion and spiral artery transformation. However, these are well-recognized
risk factors for cardiovascular morbidity, with established and plausible biological mechanisms
explaining their pathophysiological roles [43,44]. Apart from these conventional clinical risk factors,
systematic reviews of genetic risk factors demonstrated that plasminogen activator inhibitor-1 (PAI-1)
and FMS-related tyrosine kinase 1 (FLT1)—known to be linked with risks of coronary heart disease
and heart failure—were also strongly associated with preeclampsia [45–47].
6.2. Pre-Pregnancy Cardiovascular Function in Preeclampsia
If maternal risk factors for preeclampsia and adult cardiovascular disease indeed work through
the same mechanisms, then there should be evidence for pre-pregnancy cardiovascular impairment in
women destined to develop preeclampsia. Although there is a paucity of such pre-conceptual studies,
a recent study by Foo et al. longitudinally assessed cardiovascular function in 356 spontaneously
conceived pregnancies in apparently healthy women, starting from preconception. The authors noted
that the 15 (4.2%) women who developed preeclampsia and fetal growth restriction had lower cardiac
output and higher total peripheral resistance before the pre-conceptual period compared to those
with uneventful pregnancies [31]. These findings support the concept that suboptimal pre-pregnancy
cardiovascular function may predispose the woman to impaired uterine artery blood flow and poor
trophoblast development as precursors to the development of preeclampsia. This assertion is supported
by pre-conceptual echocardiographic evaluation of formerly preeclamptic women assessing their risk
of recurrent preeclampsia. Those with recurrent preeclampsia had lower cardiac left ventricular mass
and cardiac stroke volume in the pre-pregnancy period compared to women who had a normal second
pregnancy [48].
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6.3. Abnormal Cardiovascular Function in Pregnancy and Preeclampsia
First-trimester maternal cardiovascular parameters, such as mean arterial blood pressure and
uterine artery resistance, are key biomarkers in the ASPRE (Combined Multimarker Screening and
Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention) screening
algorithm that have very high accuracy for the prediction of preeclampsia, especially of preterm
onset [5]. More sophisticated echocardiographic assessment has shown cardiac remodeling, impaired
hemodynamics, and diastolic dysfunction, both in the first trimester and at mid-pregnancy in
women destined to develop preeclampsia compared to those with normal outcomes [49–51]. Even
in uncomplicated pregnancies, there are well-documented hemodynamic changes which peak in the
middle of the third trimester before the cardiac output falls and systemic vascular resistance increases—a
paradoxical finding, in view of the fact that maternal respiratory and metabolic demands continue
to increase with advancing gestation [52,53]. Echocardiographic studies have demonstrated that in
apparently healthy women with normal pregnancies, there are signs of mild cardiac maladaptation to
the volume overload, such as an excessive increase in the left ventricular remodeling with associated
diastolic dysfunction in a small but significant proportion of cases at term [54,55]. It is apparent
that even a normal pregnancy confers a previously unrealized significant workload on the maternal
cardiovascular system, and that in some cases, this results in asymptomatic cardiac dysfunction
(Figure 3).
Figure 3. Left ventricle remodelling caused by pregnancy and preeclampsia. Alteration in (volume and
pressure) loading conditions and the interaction with mechanical and neurohormonal factors results
in ventricular remodeling. At an organ level, remodeling refers to changes in ventricular geometry,
volume, and mass. Although remodelling is compensatory in certain pressure and volume overload
conditions, progressive ventricular remodeling is ultimately a maladaptive process, contributing to the
progression of symptomatic heart failure and an adverse outcome.
6.4. Cardiovascular Function in Preeclampsia
At the clinical onset of preeclampsia, significant hemodynamic impairment, such as lower
cardiac output, abnormal ventricular geometry, and diastolic dysfunction have been demonstrated
by several maternal echocardiography studies [49,56–58]. Severe preterm disease is associated with
a worse cardiovascular profile, which is in turn associated with higher rates of serious peripartum
complications, such as pulmonary edema [59–61]. In keeping with these findings, a number of
cardiovascular biomarkers, such as ANP-related proteins and Corin, have been shown to be altered in
pregnancy in women with preeclampsia [61–63].
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6.5. Abnormal Cardiovascular Function Persists after Preeclampsia
Birth is considered to be a “cure” for preeclampsia. While it is not in doubt that the signs, symptoms,
and risks of preeclampsia regress in the vast majority of women within days after birth, the paradigm
that delivery normalizes maternal health after preeclampsia is not supported by postpartum studies.
The risk for developing chronic hypertension postnatally is much higher after preeclampsia than after
normotensive pregnancy, with rates of up to 30% for chronic hypertension being reported at one year
postpartum [64]. A large register-based study of over a million women confirmed a 20-fold increase in
the rate of antihypertensive medication in pregnancies complicated by hypertensive disorders used
within the first year after birth [65]. Even in women who are normotensive postpartum, asymptomatic
moderate-severe cardiac dysfunction was significantly higher in preterm preeclampsia (56%) compared
with term preeclampsia (14%) versus matched controls [66]. The issue of whether the latter findings
were caused by preeclampsia or pre-existing was evaluated in a large Norwegian epidemiological
study, which suggested that the increased postpartum cardiovascular risk after preeclampsia may
most probably be due to pre-existing risk factors, rather than a detrimental effect of preeclampsia on
the maternal cardiovascular system [67].
7. Analogy between Preeclampsia and Diabetes in Pregnancy
There are multiple clinical similarities between hypertension and diabetes in pregnancy, despite
the fact that one is considered purely of placental origin and the other related to maternal pancreatic
dysfunction [68–70]. Both disorders are diagnosed because of new-onset hypertension or hyperglycemia
in pregnancy, predisposing risk factors are similar to adult-onset disease, the definitive treatment
is birth, and both disorders leave a post-partum legacy of disease (Figure 4). The most convincing
alignment between these two disorders is apparent when one considers the phenotypes of the disease.
Pre-gestational diabetes and preterm pre-eclampsia both reflect primary organ dysfunction, and as
such, are predisposed to pre-pregnancy disease and have a more severe, early-onset phenotype [71,72].
Gestational diabetes and term preeclampsia reflect normal organ function, being overcome by increased
vascular/glycemia load late in pregnancy, and as such, are difficult to screen for and present themselves
later in pregnancy with a milder phenotype [73].
Figure 4. Interaction between maternal cardiovascular function and placental function, maternal health,
and fetal well-being. Placental oxidative stress or hypoxia is related to the relative balance of cardiovascular
functional reserve and the cardiovascular volume/resistance load of pregnancy. The final common pathway
that results in the signs and symptoms of preeclampsia involves the release of placental vasoactive substances.
Adapted with permission from Thilaganathan and Kalafat. Hypertension. 2019;73:522–531 [68].
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8. Apparent Inconsistencies with Cardiovascular Origin Hypothesis
There are many iconic hypotheses applied to the placental origins of preeclampsia that stem out
of clinical or epidemiological associations, such as those involving parity, change in partner, assisted
reproductive technology, oocyte donation, and the “protective” effect of smoking. These hypotheses
have assumed trophoblast origins of preeclampsia in their development, and a re-examination of their
biological plausibility is justified.
8.1. Nulliparity
The risk of preeclampsia is about two times lower in multiparous women, and this has always
been attributed to desensitization after exposure to paternal antigens in the placenta during previous
pregnancies. Most epidemiological studies that report on parity and prevalence of preeclampsia
do not account for the fact that, on average, multiparous women deliver approximately one week
earlier than nulliparous women [74]. As shown in a recent randomized trial of induction of labor at
39 weeks’ gestation versus expectant management, the effect of this temporal difference is to reduce
the prevalence of preeclampsia by about 40%, thereby accounting for a significant proportion of the
different rates of preeclampsia with parity [75]. Cardiac assessment of pregnancy has also consistently
demonstrated that parous women have a more favorable cardiovascular profile throughout pregnancy
compared to nulliparous women [76,77]. Such cardiac programming is a well-accepted phenomenon
in non-pregnancy physiology, and provides a biologically plausible rationale for different rates of
preeclampsia with parity.
8.2. Change in Partner
Partner change is also considered by many to be a risk factor for preeclampsia, and is attributed to
a maternal immune reaction against new paternal antigens expressed in the placenta [78]. Despite
original studies indicating the importance of partner change as a risk factor, larger and more recent
epidemiological studies in normal and assisted conception pregnancies have demonstrated that partner
change is a proxy for lengthening inter-pregnancy intervals and advanced maternal age. Skjaerven
and colleagues have demonstrated that a change of partner is not associated with an increased risk of
preeclampsia after adjustment for the interval between births and maternal age [79,80].
8.3. Oocyte Donation
The increased risk of preeclampsia with assisted conceptions was shown to be attributable to
advanced maternal age and oocyte donation [81,82]. The influence of oocyte donation as a risk factor is
in alignment with disrupted immunological tolerance, as previously postulated, until one considers that
women who conceive by egg donation tend to be older, affected by premature ovarian failure, or have
mosaic Turner syndrome—and all these factors are known to increase cardiovascular risk [83,84].
8.4. Smoking
While it is well-established that smoking increases risk for poor fetal growth, its relation to
preeclampsia is more controversial and not consistent with the placental origins hypothesis considering
that a meta-analysis showed that smoking is inversely associated with the incidence of preeclampsia [85].
However, smoking is known to increase maternal carbon monoxide levels, which inhibit levels of sFlt-1
and increase those of PlGF—the opposite of what occurs in preeclampsia [86,87]. Furthermore, carbon
monoxide also has a protracted hypotensive effect, which would decrease the diagnosis of high blood
pressure and, as a consequence, paradoxically reduce the prevalence of preeclampsia whilst increasing
the risk of poor fetal growth [88].
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9. Conclusions
Placental cellular function and development may be controlled by maternal systemic and
local uterine cardiovascular perfusion, rather than vice versa. The key role of the placenta
and its discarded products in causing maternal endothelial disfunction during pregnancy is
doubtless; nevertheless, the predisposition of women with cardiovascular dysfunction for developing
preeclampsia, the development of cardiovascular dysfunction prior to disease onset, the predominance
of cardiovascular signs/biology at presentation, and the long-term cardiovascular health risks
post-partum all support the assertion that preeclampsia could be a primary cardiovascular disorder.
Significant advances in screening, diagnosis, management, and post-partum cardiovascular health
after preeclampsia may occur as we acknowledge this paradigm shift in disease causality.
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